Navigation Links
Anthera Announces Fourth Quarter 2011 Financial Report and Conference Call
Date:2/9/2012

HAYWARD, Calif., Feb. 9, 2012 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, will release its fourth quarter 2011 financial report before the market opens on Tuesday, February 21, 2012. Anthera will host a conference call at 1 pm Eastern Time in conjunction with the release. The Company will also provide an update for both the varespladib and blisibimod clinical programs. Conference Call Access:Date:

Tuesday, February 21, 2012Time:

1:00 pm Eastern Time

Domestic Dial-in:

(877) 312-8807International Dial-in:

(253) 237-1190Conference ID:

47038854

To access the 24-hour audio replay, U.S. and Canadian participants may dial (855) 859-2056; international participants may dial (404) 537-3406.  The conference ID for the replay is 47038854. The audio replay will be available until February 28, 2012. 

About Anthera PharmaceuticalsAnthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases.  Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623).  Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2).  Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease.  Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF), which have been associated with a variety of B-Cell mediated autoimmune diseases, includi
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
2. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
3. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
4. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
5. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
6. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
8. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
9. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
11. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 3SBio Inc. (NASDAQ: ... China -based biotechnology company focused ... announced today that, at an extraordinary general meeting ... in favor of the proposal to authorize and ... merger dated February 8, 2013, among Decade Sunshine ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 Neurocrine ... Kevin Gorman , President and Chief Executive ... Bank 38 th Annual dbAccess Health Care Conference in ... Thursday, May 30 at 11:20 a.m. Eastern Time / 8:20 ... be accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... , CONCORD, Calif. , Feb. 3 Pulse Systems ... the Western United States . Effective February 1, 2010 , Diverse ... exclusive sales territory encompassing the states of California (except for the ... Oregon , Washington , Colorado , Utah , Idaho ...
... , VIENNA, Va. , Feb. 3 ... , Chief Executive Officer, will be presenting at the 2010 BIO ... the conference will take place February 8-9 at the ... be on Tuesday, February 9th , at 1:30 p.m. ...
Cached Medicine Technology:Pulse Systems Announces New Sales Representation in the Western United States 2Pulse Systems Announces New Sales Representation in the Western United States 3CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference 2
(Date:5/24/2013)... According to the new market research report “Micro Irrigation ... published by MarketsandMarkets, global micro irrigation system market expected ... year 2010 and is expected to reach $3,414.7 million ... 2011 to 2016. , Browse:, , ... , 370 pages and in-depth Table Of ...
(Date:5/24/2013)... Pittsburgh, PA (PRWEB) May 24, 2013 ... may be more likely to suffer from gastroesophageal reflux ... physicians reported in a study published today. , ... and Abnormal Proximal Exposure as Measured by Hypopharyngeal Multichannel ... “These findings could be of great importance to individuals ...
(Date:5/24/2013)... 24, 2013 For the second consecutive ... Fresh Express Café to treat Tabitha Meals on Wheels ... their door. More than 400 meal recipients recently enjoyed ... restaurants, along with the rest of a well-balanced, nutritious ... to partner with the Tabitha Meals on Wheels team,” ...
(Date:5/24/2013)... May 24, 2013 With today’s levels of ... hunting for advice on the causes of weight gain and ... developed that suggest causes of weight gain and treatments that ... study was released by the Child Study Center at ... the childhood diagnosis of ADHD and the soring rates of ...
(Date:5/24/2013)... Today marks the launch of Destination Halifax’s latest ... The redesigned and enhanced Itinerary Builder will help visitors ... computer or mobile device that they can send, save, ... to fill in their date of arrival and length ... of vacation packages, accommodations, restaurants, and things to do ...
Breaking Medicine News(10 mins):Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 2Health News:Micro Irrigation System Market to Reach $3414.7 Million by 2016 at a CAGR of 17.9% - New Report by MarketsandMarkets 3Health News:West Penn Allegheny Health System Physicians Pinpoint Gastroesophageal Reflux Disease (GERD) as a Factor That May Cause Chronic Cough 2Health News:Runza® Delivers Sandwiches, Draws Smiles from Tabitha Meals on Wheels Clients 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Now Help Patients with Weight Gain Linked to Childhood ADHD Lose Weight Fast 2Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2
... Steve TyrellSpecial Performance by Dancing With The Stars ... actress Bonnie Hunt will receive the "True ... Harvey Rosen will receive "The Duke" ... 24th annual Odyssey Ball. The yearly fundraising ...
... added section on hospital care and advice on drugs ... News) -- New guidelines for treatment of heart failure ... the American College of Cardiology, with a strong emphasis ... also on the treatment of blacks. , "The most ...
... Survey conducted by the Society of Corporate Compliance and ... In the face of reports on AIG bonuses it ... of the gifts employees can give and receive and ... a survey the Society of Corporate Compliance and Ethics ...
... Possis Acquisition and Patient Care Innovations WARRENDALE, Pa., ... over $600 million in 2008, an increase of ... (excluding the effect of the Possis Medical, Inc. ... and therapeutic medical devices, MEDRAD has achieved a ...
... Software Upgrade Enhances Company,s Lead in Data Quality, ... AnalysisPITTSBURGH, March 26 Neuro Kinetics, Inc. (NKI) ... evaluation equipment used worldwide for balance, vestibular and ... release version 6.7 of its proprietary VEST(TM) control ...
... (NYSE Amex: DPW ) today announced its financial ... December 31, 2008.Digital Power reported net income of $142,000 for ... income of $235,000 for the three months ended December 31, ... 2008, compared to operating income of $206,000 for the fourth ...
Cached Medicine News:Health News:John Wayne Cancer Institute Auxiliary Honors Award-Winning Actress Bonnie Hunt and Philanthropists Donna & Harvey Rosen at the 24th Annual Odyssey Ball 2Health News:New Guidelines for Treating Heart Failure 2Health News:New Guidelines for Treating Heart Failure 3Health News:Bonuses May be Big but Don't Expect a Lavish Dinner or Gift 2Health News:MEDRAD(R) Revenues Grow 10 Percent in 2008 2Health News:MEDRAD(R) Revenues Grow 10 Percent in 2008 3Health News:MEDRAD(R) Revenues Grow 10 Percent in 2008 4Health News:Neuro Kinetics to Release VEST(TM) 6.7 Software at Audiology Conference 2Health News:Neuro Kinetics to Release VEST(TM) 6.7 Software at Audiology Conference 3Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 2Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 3Health News:Digital Power Reports Financial Results for the Fourth Quarter and the Year Ended December 31, 2008 4
... Used for stone manipulation and ... Enhanced wire strength permits the ... more readily than standard flat-wire ... easy, ergonomic one-handed operation. Supplied ...
... manipulation and removal in the urinary tract. The ... its shape following extreme torsion. The unique tipless ... the basket to open at the base of ... design reduces the likelihood of mucosal damage and ...
Used to establish and maintain nephrostomy drainage following pyeloplasty. Supplied sterile in peel-open packages. Intended for one-time use. CAUTION: Periodic evaluation is advised; stent must not r...
... Analyzer is an in vitro diagnostic ... chemistry parameters using Reflotron Test Tabs. It works ... rapid and reliable results while being easy to ... display and the profile can be printed out ...
Medicine Products: